Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.

Sakthianandeswaren A, Parsons M, Mouradov D, MacKinnon RN, Catimel B, Liu S, Palmieri M, Love CG, Jorissen RN, Li S, Whitehead L, Putoczki TL, Preaudet A, Tsui C, Nowell CJ, Ward RL, Hawkins NJ, Desai J, Gibbs P, Ernst M, Street I, Buchert M, Sieber OM.

Cancer Discov. 2018 Jun 7. pii: CD-17-0909. doi: 10.1158/2159-8290.CD-17-0909. [Epub ahead of print]

PMID:
29880585
2.

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM.

Gut. 2018 Jan 30. pii: gutjnl-2017-315664. doi: 10.1136/gutjnl-2017-315664. [Epub ahead of print]

PMID:
29382774
3.

Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.

Wang J, Mouradov D, Wang X, Jorissen RN, Chambers MC, Zimmerman LJ, Vasaikar S, Love CG, Li S, Lowes K, Leuchowius KJ, Jousset H, Weinstock J, Yau C, Mariadason J, Shi Z, Ban Y, Chen X, Coffey RJC, Slebos RJC, Burgess AW, Liebler DC, Zhang B, Sieber OM.

Gastroenterology. 2017 Oct;153(4):1082-1095. doi: 10.1053/j.gastro.2017.06.008. Epub 2017 Jun 16.

PMID:
28625833
4.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

5.

Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.

Suraweera N, Mouradov D, Li S, Jorissen RN, Hampson D, Ghosh A, Sengupta N, Thaha M, Ahmed S, Kirwan M, Aleva F, Propper D, Feakins RM, Vulliamy T, Elwood NJ, Tian P, Ward RL, Hawkins NJ, Xu ZZ, Molloy PL, Jones IT, Croxford M, Gibbs P, Silver A, Sieber OM.

Oncotarget. 2016 Jun 14;7(24):36474-36488. doi: 10.18632/oncotarget.9015.

6.

Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.

Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, Xu ZZ, Molloy PL, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Lipton L, Desai J, Gibbs P, Sieber OM.

Br J Cancer. 2015 Sep 15;113(6):979-88. doi: 10.1038/bjc.2015.296. Epub 2015 Aug 25.

7.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
8.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.

Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Faragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B.

Acta Oncol. 2015 Apr;54(4):487-92. doi: 10.3109/0284186X.2014.990158. Epub 2014 Dec 31. Erratum in: Acta Oncol. 2017 Feb;56(2):375.

9.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM.

Cancer Res. 2014 Jun 15;74(12):3238-47. doi: 10.1158/0008-5472.CAN-14-0013. Epub 2014 Apr 22.

10.

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.

Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D, Novelli M, Yau C, Holmes CC, Jones IT, McLaughlin S, Molloy P, Hawkins NJ, Ward R, Midgely R, Kerr D, Tomlinson IP, Sieber OM.

Am J Gastroenterol. 2013 Nov;108(11):1785-93. doi: 10.1038/ajg.2013.292. Epub 2013 Sep 17.

PMID:
24042191
11.

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.

Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Clin Cancer Res. 2013 Jun 15;19(12):3285-96. doi: 10.1158/1078-0432.CCR-12-3614. Epub 2013 Apr 30.

12.

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.

Zapparoli GV, Jorissen RN, Hewitt CA, McBean M, Westerman DA, Dobrovic A.

BMC Cancer. 2013 Apr 24;13:206. doi: 10.1186/1471-2407-13-206.

13.

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.

Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Cancer Res. 2013 Jan 15;73(2):725-35. doi: 10.1158/0008-5472.CAN-12-2706. Epub 2012 Nov 8.

14.

Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.

Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, Busam D, Zhao Q, Strausberg RL, Simpson AJ, Tomlinson IP, Gibbs P, Sieber OM.

Oncogene. 2013 Sep 26;32(39):4675-82. doi: 10.1038/onc.2012.486. Epub 2012 Oct 22.

15.

PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis.

Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, Segditsas S, Tomlinson IP, Bernhard OK, Simpson RJ, Walker F, Faux MC, Church N, Catimel B, Flanagan DJ, Vincan E, Sieber OM.

Cancer Res. 2011 May 15;71(10):3709-19. doi: 10.1158/0008-5472.CAN-10-2342. Epub 2011 May 10.

16.

KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.

Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans PM, Pick AW, Knight S, Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM.

Clin Cancer Res. 2011 Mar 1;17(5):1122-30. doi: 10.1158/1078-0432.CCR-10-1720. Epub 2011 Jan 14.

17.

Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability.

Williams DS, Bird MJ, Jorissen RN, Yu YL, Walker F, Zhang HH, Nice EC, Burgess AW.

PLoS One. 2010 Dec 31;5(12):e16012. doi: 10.1371/journal.pone.0016012. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/53805ecf-7d10-4d99-9cec-f27f5e0d4166. Walker, Franscesa [corrected to Walker, Francesca].

18.

A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data.

Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G, Harris A, Ragoussis J, Sieber O, Holmes CC.

Genome Biol. 2010;11(9):R92. doi: 10.1186/gb-2010-11-9-r92. Epub 2010 Sep 21.

19.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.

Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.

20.

Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases.

Ia KK, Mills RD, Hossain MI, Chan KC, Jarasrassamee B, Jorissen RN, Cheng HC.

Growth Factors. 2010 Oct;28(5):329-50. doi: 10.3109/08977194.2010.484424. Review.

PMID:
20476842
21.

Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.

Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM.

Clin Cancer Res. 2009 Dec 15;15(24):7642-7651.

22.

Additivity in the analysis and design of HIV protease inhibitors.

Jorissen RN, Reddy GS, Ali A, Altman MD, Chellappan S, Anjum SG, Tidor B, Schiffer CA, Rana TM, Gilson MK.

J Med Chem. 2009 Feb 12;52(3):737-54. doi: 10.1021/jm8009525.

23.

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.

Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP, Verspaget HW, Aaltonen LA, Kruhøffer M, Orntoft TF, Andersen CL, Sieber OM.

Clin Cancer Res. 2008 Dec 15;14(24):8061-9. doi: 10.1158/1078-0432.CCR-08-1431.

24.

BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities.

Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK.

Nucleic Acids Res. 2007 Jan;35(Database issue):D198-201. Epub 2006 Dec 1.

25.

Virtual screening of molecular databases using a support vector machine.

Jorissen RN, Gilson MK.

J Chem Inf Model. 2005 May-Jun;45(3):549-61.

PMID:
15921445
26.

CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

Walker F, Orchard SG, Jorissen RN, Hall NE, Zhang HH, Hoyne PA, Adams TE, Johns TG, Ward C, Garrett TP, Zhu HJ, Nerrie M, Scott AM, Nice EC, Burgess AW.

J Biol Chem. 2004 May 21;279(21):22387-98. Epub 2004 Mar 11.

27.

Epidermal growth factor receptor: mechanisms of activation and signalling.

Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW.

Exp Cell Res. 2003 Mar 10;284(1):31-53. Review.

PMID:
12648464
28.

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW.

Mol Cell. 2003 Feb;11(2):495-505.

29.

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW.

Cell. 2002 Sep 20;110(6):763-73.

30.

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.

Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, Suzuki-Takahashi I, Jorissen RN, Burgess AW, Nishimura S, Wood J, Maruta H.

Cancer J. 2002 Jul-Aug;8(4):328-36.

PMID:
12184411
31.

Rapid microscale enzymic semisynthesis of epidermal growth factor (EGF) analogues.

Nice EC, Domagala T, Fabri L, Nerriea M, Walker F, Jorissen RN, Burgess AW, Cui DF, Zhang YS.

Growth Factors. 2002 Jun;20(2):71-80.

PMID:
12148565
32.

Modeling the epidermal growth factor -- epidermal growth factor receptor l2 domain interaction: implications for the ligand binding process.

Jorissen RN, Treutlein HR, Epa VC, Burgess AW.

J Biomol Struct Dyn. 2002 Jun;19(6):961-72.

PMID:
12023799
33.

Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain.

Elleman TC, Domagala T, McKern NM, Nerrie M, Lönnqvist B, Adams TE, Lewis J, Lovrecz GO, Hoyne PA, Richards KM, Howlett GJ, Rothacker J, Jorissen RN, Lou M, Garrett TP, Burgess AW, Nice EC, Ward CW.

Biochemistry. 2001 Jul 31;40(30):8930-9.

PMID:
11467954
34.

Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor.

Domagala T, Konstantopoulos N, Smyth F, Jorissen RN, Fabri L, Geleick D, Lax I, Schlessinger J, Sawyer W, Howlett GJ, Burgess AW, Nice EC.

Growth Factors. 2000;18(1):11-29.

PMID:
10831070
35.

Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor.

Jorissen RN, Epa VC, Treutlein HR, Garrett TP, Ward CW, Burgess AW.

Protein Sci. 2000 Feb;9(2):310-24.

Supplemental Content

Loading ...
Support Center